350 Folgen

  1. 268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading

    Vom: 27.7.2023
  2. 267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford

    Vom: 20.7.2023
  3. 266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads

    Vom: 13.7.2023
  4. 265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market

    Vom: 29.6.2023
  5. 264: Messy PBM conflicts, debatable vaccines, & the future of flu season

    Vom: 22.6.2023
  6. 263: Biogen's messy board, Laronde's data problem, & the downside of a boom

    Vom: 15.6.2023
  7. 262: Merck v. USA, the best of ASCO, and Leqembi at the FDA

    Vom: 8.6.2023
  8. 261: Fake medical devices, real cancer drugs, & curious Ozempic effects

    Vom: 1.6.2023
  9. 260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA

    Vom: 25.5.2023
  10. 259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround

    Vom: 18.5.2023
  11. 258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry

    Vom: 11.5.2023
  12. 257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business

    Vom: 4.5.2023
  13. 256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval

    Vom: 27.4.2023
  14. 255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters

    Vom: 20.4.2023
  15. 254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future

    Vom: 13.4.2023
  16. 253: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers

    Vom: 6.4.2023
  17. 252: Biotech's monkey shortage, the broken generics market, & conference cancel culture

    Vom: 30.3.2023
  18. 251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster

    Vom: 23.3.2023
  19. 250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

    Vom: 16.3.2023
  20. 249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

    Vom: 9.3.2023

5 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site